Apoptotic markers p53, Bcl-2 and bax in primary lung cancer

In Vivo

Volumn 20, Issue 5, 2006, Pages 599-604

  Porebska, Irena ^a   Wyrodek, Ewa ^a   Kosacka, Monika ^a   Adamiak, Jaroslaw ^b   Jankowska, Renata ^a   Harłozinska Szmyrka, Antonina ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Lower Silesian Centre of Lung Diseases   (Poland)

Author keywords

Bax; Bcl 2; Lung cancer; p53

Indexed keywords

CELL MARKER; PARAFFIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BIOACCUMULATION; BRONCHUS MUCOSA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENETIC HETEROGENEITY; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; MALE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TISSUE STRUCTURE;

EID: 33750584219     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Soussi T: The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 910: 121-137, 2000.
2. Cory S, Huang CSD and Adams MJ: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590-8607, 2003.
3. Groeger AM, Esposito V, De Luca A, Cassandro R, Tonini G, Ambrogi V, Baldi F, Goldfarb R, Mineo TC, Baldi A and Wolner E: Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-x in resected non-small cell lung cancers. Histopathology 44: 54-63, 2004.
4. Mori S, Ito G, Usami N, Yoshioka H, Ueda Y, Kodama Y, Takahashi M, Fong KM, Shimokata K and Sekido Y: p53 apoptotic pathway molecules are frequently and simultaneously altered in non-small cell lung carcinoma. Cancer 15: 1673-1682, 2004.
5. Shabnam MS, Srinivasan R, Wali A, Majumdar S, Joshi K and Behera D: Expression of p53 protein and the apoptotic regulatory molecules Bel-2, Bcl-XL and Bax in locally advanced squamous cell carcinoma of the lung Lung Cancer 45: 181-188, 2004.
6. Brambilla E, Travis WD, Colby TV, Corrin B and Shimosato Y: The new World Health Organization classificantion of lung tumors. Eur Respir J 18: 1059-1068 2001.
7. Beahrs OH, Henson DE, Hutter RVP and Kennedy BJ: Lung Manual for Staging of Cancer, 4th edition. Chicago American Joint Committee on Cancer, pp. 115-122, 1992.
8. Hwang JH, Lim SC, Kim YC, Park KO, Alm SJ and Chung WK: Apoptosis and bcl-2 expression as predictors of survival in radiation-treated non-small cell lung cancer. Int J Radiat Oncol Biol Phys 50: 13-18, 2001.
9. Gregorc V, Ludovini V, Pistola L Darwish S, Floriani I, Beflezza G, Sidoni A, Cavaliere A, Scheibel M, De Angelis V, Bucciarelli E and Tonato M: Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 39: 41-48, 2003.
10. Borner MM, Brousset P, Pfanner-Meyer B, Bacchi M, Vonlanthen S, Hotz MA, Altermatt HJ, Schlaifer D, Reed JC and Betticher DC: Expression of apoptosis regulatory proteins of Bcl-2 family and p53 in primary resected lung cancer. Br J Cancer 79: 952-958, 1999.
11. Walker C, Robertson LJ, Myskow MW, Pendleton N and Dixon GR: p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer 70: 297-303, 1994.
12. Ohsaki Y, Toyoshima E, Fujiuchi S, Matsui H, Hirata S, Miyokawa N, Kubo Y and Kikuchi K: Bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res 2: 915-920, 1996.
13. Shibata Y, Hidaka S, Tagawa Y and Nagayasu T: Bcl-2 protein expression correlates with better prognosis in patients with advanced non-small cell lung cancer. Anticancer Res 24: 1925-1928, 2004.
14. Laudanski J, Chyczewski L, Niklinska WE Kretowska M, Furman M, Sawicki B and Niklinski J: Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival. Neoplasma 46: 25-30, 1999.
15. Krug LM, Miller VA, Filippa DA Venkatraman E, Ng KK and Kris MG: Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine. Lung Cancer 39: 139-143, 2003.
16. Walker C, Robertson L, Myskow MW and Dixon GR: Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer 72: 164-169, 1995.
17. Jeanmart M, Lantuejoul S, Fievet F, Moro D, Sturm N, Brambilla Ch and Brambilla E: Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. Clin Cancer Res 9: 2195-2203, 2003.
18. Moldvay J, Scheid P, Wild P Nabil K, Siat J, Borrelly J, Marie B, Farre G, Labib T, Pottier G, Sesboue R, Bronner C, Vignaud JM, Martinet Y and Martinet N: Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res 6: 1125-1134, 2000.
19. Greatens TM, Niehans GA, Rubins JB Jessurun J, Kratzke RA Maddaus MA and Niewoehner DE: Do molecular markers predict survival in non-small cell lung cancer? Am J Respir Crit Care Med 157. 1093-1097, 1998.
20. Appolinairo RM, van der Valk P, de Jong JS, Deville W, van Ark-Otte J, Dingemans AM, van Mourik JC, Postmus PE, Pinedo HM and Giaccone G: Prognostic value of the expression of p53, bel-2 and bax oncoproteins and neovascularisation in patients with radically resected non-small-cell lung cancer. J Clin Oncol 15: 2456-2466, 1997.
21. Dursun BA, Memis L, Dursun A, Bayiz H and Ozkul M: Clinical importance of correlations between p53 immunoreactivity and clinicopathological parameters in lung carcinoma. Pathol Oncol Res 5: 285-290, 1999.